Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A

BACKGROUND: Emicizumab is a humanized bispecific monoclonal antibody that bridges activated factor IX (FIXa) and factor X (FX) to mimic the function of factor VIII (FVIII). It suppresses the bleeding tendency in hemophilia A patients with or without FVIII inhibitors. A case of an adult FVIII inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneda, Makoto, Kawasaki, Ryohei, Matsumoto, Naoki, Abe, Hiroto, Tashiro, Yoshihito, Inokuchi, Yuta, Yasuno, Hideyuki, Sasaki‐Noguchi, Mariko, Soeda, Tetsuhiro, Yoshimura, Yasushi, Oka, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292660/
https://www.ncbi.nlm.nih.gov/pubmed/34418287
http://dx.doi.org/10.1111/jth.15506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292660/
https://www.ncbi.nlm.nih.gov/pubmed/34418287
http://dx.doi.org/10.1111/jth.15506

Ejemplares similares